Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle
Amgen's dazodalibep Phase 3 trial met its primary endpoint in systemic Sjögren's disease, sending AMGN shares higher on 22 September 2026.
Markets
Delayed · 13:29 UK
Topic
Every Financial News story tagged AMGN, newest first.
Amgen's dazodalibep Phase 3 trial met its primary endpoint in systemic Sjögren's disease, sending AMGN shares higher on 22 September 2026.